New data from TWILIGHT – a Phase IV independent trial funded by AstraZeneca – showed that in patients at high-bleeding risk who underwent PCI and completed three months of dual antiplatelet therapy, Brilinta monotherapy (90 mg twice daily) reduced the risk of BARC (Bleeding Academic Research Consortium) type 2, 3 or 5 bleeding compared to Brilinta plus low-dose aspirin after 12 months.
PhaseBio Receives FDA Breakthrough Therapy Designation and Licenses GLP-1 Analog to ImmunoForge
Antiplatelet Drugs, Breakthrough Therapy Designation, FDA, FDA/Regulatory, Glucagon-Like Peptide-1 (GLP-1) Analogs, Heart Attacks, Monoclonal Antibodies, Muscle loss, Pulmonary Arterial Hypertension, Sarcopenia, StrokesPhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.
